Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC)
Owonikoko, Taofeek Kunle, Borghaei, Hossein, Champiat, Stéphane, Paz-Ares, Luis G., Govindan, Ramaswamy, Boyer, Michael J., Johnson, Melissa Lynne, Udagawa, Hibiki, Hummel, Horst-Dieter, Salgia, Ravi, Blackhall, Fiona Helen, Boosman, Rene J., Lai, Wei-Chu Victoria, Dowlati, Afshin, Vokes, Everett E., Hann, Christine L., Chiang, Anne C., Endraca, Marichu, Soman, Neelesh, Smit, Marie-Anne Damiette
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article